New triazole derivatives with nematicidal activity

Anna Bogucka-Kocka¹, Przemysław Kołodziej², Monika Wujec³, Janusz Kocki⁴

¹Chair and Department of Biology and Genetics, Medical University of Lublin, Chodźki 4A, 20-093 Lublin, Poland ²Chair and Department of Biology and Genetics, Laboratory of Diagnostic Parasitology, Medical University of Lublin, Chodźki 4A, 20-093 Lublin, Poland

³Department of Organic Chemistry, Medical University of Lublin, Chodźki 4A, 20-093 Lublin, Poland ⁴Department of Clinical Genetics, Medical University of Lublin, Radziwiłłowska 11, 20-080 Lublin, Poland

Corresponding author: Przemysław Kołodziej; e-mail: przemyslawkolodziej@umlub.pl

The increasing frequency of parasitic diseases caused by nematodes and the increasing drug resistance of parasites to the available drugs induce the need to search for new, effective nematicidal drugs. Parasitic diseases constitute a serious health problem and may pose a threat to human health and life. According to data presented by the World Health Organization, 14 million people die each year from parasitic diseases, and over the past 10 years, more than 4.5 billion people have become infected with various species of parasites. Currently, a very narrow group of nematicidal drugs is available on the market: benzimidazole derivatives – mebendazole and albendazole (bind to nematode β -tubulin, inhibiting the formation of microtubules, blocking the absorption of glucose inside the parasite cells), cyanines and cyclic amidines, i.e. pyrantel (leads to paralysis of parasites by depolarizing the motor muscle-nerve plate), avermeetin derivatives – ivermeetin (stimulates the release of γ -aminobutyric acid (GABA), causing disturbances in nerve conduction in nematodes). The compounds tested by us are newly synthesized triazole derivatives with proven in research – carried out on the basis of a proprietary, patent-protected procedure, using nematodes of the genus *Rhabditis* sp., – nematicidal activity. The synthesis process and the nematicidal activity are protected by patents.